Download App

Log in to access Online Inquiry
Company Overview More
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
CEO: Fischer, Laurent
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

ADVM Adverum Biotechnologies

0.816+0.006+0.74%
Trading Session 05/17 11:06 ET
High
0.852
Open
0.830
Turnover
198.65K
Low
0.810
Pre Close
0.810
Volume
242.11K
Market Cap
80.57M
P/E(TTM)
Loss
52wk High
3.860
Shares
98.77M
P/E(Static)
Loss
52wk Low
0.795
Float Cap
63.65M
Bid/Ask %
0.00%
Historical High
62.480
Shs Float
78.03M
Volume Ratio
0.60
Historical Low
0.795
Dividend TTM
--
Div Yield TTM
--
P/B
0.28
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.31%
Amplitude
5.14%
Avg Price
0.820
Lot Size
1
Float Cap
63.65M
Bid/Ask %
0.00%
Historical High
62.480
Shs Float
78.03M
Volume Ratio
0.60
Historical Low
0.795
Dividend TTM
--
P/B
0.28
Dividend LFY
--
Turnover Ratio
0.31%
Amplitude
5.14%
Avg Price
0.820
Lot Size
1
Price Forecast

No Data

News

Comment